Ractigen announces China Phase 2 study initiation for RAG-01 in bladder cancer
Company / institutional announcement · Ractigen Therapeutics
Source published: · Event / reporting date: 2026-11-02
Site published: 2026-11-07 · Updated: 2026-11-07
This source is linked automatically. Choose a question to get started.
What changed
On November 2, Ractigen Therapeutics announced initiation of RAG010201, led by Fudan University Shanghai Cancer Center. The China Phase 2 study evaluates intravesical RAG-01 alone and with mitomycin C in intermediate- or high-risk non-muscle-invasive bladder cancer, using a safety run-in and separate cohorts. Site initiation does not establish enrollment completion or efficacy.
Why it may matter
Analysis: This is a development milestone for locally delivered RNA activation. Here, saRNA means small activating RNA, not self-amplifying mRNA.
The interpretation above is analysis, not a conclusion attributed to the original source.
Read the original source ↗Prepared through Biotech Assistant’s automated research workflow. Editorial standards and corrections